These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 1143089)
21. Dietary rat models in which the development of hypertriglyceridemia and that of insulin resistance are dissociated. Boivin A; Deshaies Y Metabolism; 1995 Dec; 44(12):1540-7. PubMed ID: 8786721 [TBL] [Abstract][Full Text] [Related]
22. The relationship between insulin secretion and triglyceride concentration in endogenous lipemia. Eaton BP; Nye WH J Lab Clin Med; 1973 May; 81(5):682-95. PubMed ID: 4349136 [No Abstract] [Full Text] [Related]
23. Endogenous glucagon regulation in genetically hyperlipemic obese rats. Eaton RP; Conway M; Schade DS Am J Physiol; 1976 May; 230(5):1336-41. PubMed ID: 1275076 [TBL] [Abstract][Full Text] [Related]
24. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. Kesäniemi YA; Grundy SM JAMA; 1984 May; 251(17):2241-6. PubMed ID: 6368883 [TBL] [Abstract][Full Text] [Related]
25. The influence of plasma triglycerides on human growth hormone response to arginine and insulin: a study in hyperlipemics and normal subjects. Muggeo M; Tiengo A; Fedele D; Crepaldi G Horm Metab Res; 1975 Sep; 7(5):367-74. PubMed ID: 1183914 [TBL] [Abstract][Full Text] [Related]
26. Hepatic steatosis and the elevated plasma insulin level in patients with endogenous hypertriglyceridemia. Maruhama Y; Ohneda A; Tadaki H; Ohtsuki M; Yanbe A Metabolism; 1975 May; 24(5):653-64. PubMed ID: 1128234 [TBL] [Abstract][Full Text] [Related]
27. Increase of the lipoprotein-lipase activity in human skeletal muscle during clofibrate administration. Lithell H; Boberg J; Hellsing K; Lundqvist G; Vessby B Eur J Clin Invest; 1978 Apr; 8(2):67-74. PubMed ID: 417937 [TBL] [Abstract][Full Text] [Related]
28. The direct relationship of proinsulin-insulin hypersecretion to basal serum levels of cholesterol and triglyceride in myotonic dystrophy. Poffenbarger PL; Bozefsky T; Soeldner JS J Lab Clin Med; 1976 Mar; 87(3):384-96. PubMed ID: 765416 [TBL] [Abstract][Full Text] [Related]
29. [Triglycerides, free fatty acids and cholesterol after fat loading and heparin injection in diabetics with and without hyperlipoproteinemia as well as after clofibrate treatment]. Singer P; Gnauck G; Honigmann G; Thoelke H; Schliack V; Läuter J Dtsch Z Verdau Stoffwechselkr; 1977; 37(1):27-37. PubMed ID: 913315 [No Abstract] [Full Text] [Related]
30. Suppression and stimulation mechanisms controlling glucagon secretion in a case of islet-cell tumor producing glucagon, insulin, and gastrin. Tiengo A; Fedele D; Marchiori E; Nosadini R; Muggeo M Diabetes; 1976 May; 25(5):408-12. PubMed ID: 5326 [TBL] [Abstract][Full Text] [Related]
31. Glucose modulation of insulin and glucagon secretion is altered in impaired glucose tolerance. Larsson H; Berglund G; Ahrén B J Clin Endocrinol Metab; 1995 Jun; 80(6):1778-82. PubMed ID: 7775622 [TBL] [Abstract][Full Text] [Related]
32. Effect of added fat on plasma glucose and insulin response to ingested potato in individuals with NIDDM. Gannon MC; Ercan N; Westphal SA; Nuttall FQ Diabetes Care; 1993 Jun; 16(6):874-80. PubMed ID: 8325201 [TBL] [Abstract][Full Text] [Related]
33. Interrelationships among insulin's antilipolytic and glucoregulatory effects and plasma triglycerides in nondiabetic and diabetic patients with endogenous hypertriglyceridemia. Yki-Järvinen H; Taskinen MR Diabetes; 1988 Sep; 37(9):1271-8. PubMed ID: 3044892 [TBL] [Abstract][Full Text] [Related]
34. The effect of short term physiological elevations of plasma glucagon concentration on plasma triglyceride concentration in normal and diabetic man. Schade DS; Eaton RP Horm Metab Res; 1977 Jul; 9(4):253-7. PubMed ID: 892688 [TBL] [Abstract][Full Text] [Related]
35. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855 [TBL] [Abstract][Full Text] [Related]
36. Mechanism of the hypolipemic effect of clofibrate in postabsorptive man. Wolfe BM; Kane JP; Havel RJ; Brewster HP J Clin Invest; 1973 Sep; 52(9):2146-59. PubMed ID: 4353773 [TBL] [Abstract][Full Text] [Related]
37. Treatment of hypertriglyceridemia with para-aminosalicylic acid-C: a possible mechanism of action. Goldberg AP; Chen M; Brunzell JD; Bierman EL; Porte D Metabolism; 1978 Nov; 27(11):1648-60. PubMed ID: 703606 [TBL] [Abstract][Full Text] [Related]
38. Diurnal patterns of triglycerides, free fatty acids, blood sugar, and insulin during carbohydrate-induction in man and their modification by nocturnal suppression of lipolysis. Schlierf G; Dorow E J Clin Invest; 1973 Mar; 52(3):732-40. PubMed ID: 4685092 [TBL] [Abstract][Full Text] [Related]
39. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091 [TBL] [Abstract][Full Text] [Related]
40. Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia. Feldman EB; Gluck FB; Carter AC J Clin Pharmacol; 1978; 18(5-6):241-8. PubMed ID: 346616 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]